RE:RE:RE:RE:FinancesAbsolutely. IMHO the next step is demonstrating proof of concept for low level radiation activation of rutherrin delivered systemically. If it works well with GBM and/or NSCLC this could open the door for even more cancer indications. And then there are all these new photosensitizers Dr. McFarland has been working on and Theralase has the rights to use. She has done a lot of work finding more potent PS's that work even better than TLD1433 in low oxygen environments and are very effective against melanoma and breast cancer.
ScienceFirst wrote: Eoganacht ... A JV at this stage is THE solution. It would bring upfront money as our NMIBC R&D and Ph. 2 data are worth something.
A JV is the plan to then go demonstrate that our technology can also succeed in other indications. That's the way it usually work in the industry. A big pharma would have problem justifying paying let's say 10B for something that has just been tested on one indication, especially that NSCLC and GBM are complex ones to destroy and different in terms of procedures (NMIBC is an empty space, GBM is a solid space and NSCLC has its own challenges (kind of a tree).